These are news releases that are related to our Investor efforts. Releases are listed in chronological order and are archived by year. Sign-up to receive news as it is released using the email and RSS tools below.
Jun 21, 2016Therapix Biosciences signed a binding MOU with a Swiss pharmaceutical development company, to receive a license to use a formulation for ultralow-dosage administrationSuch technology facilitates the administration and maximal absorption of the active ingredient THC via a sublingual tablet, with a view to provide a response for the indications on which the Company has chosen to focus
Tel Aviv, Israel. Therapix Biosciences, (OTCQB: THXBY) (TASE: THXBY.TA), the pharma company specializing in the development and commercialization of cannabinoid-based drugs, announced today...
Jun 15, 2016Therapix Biosciences filed an application with the FDA to approve an “orphan” designation for the drug developed based on the entourage technology for treating Tourette’s syndromeThe application was filed after completion of the pre-clinical phase and proof-of-concept of the entourage technology and further to the Company’s preparations towards clinical trials in humans
Tel Aviv, Israel. Therapix Biosciences, (OTCQB: THXBY) (TASE: THXBY.TA) the pharma company specializing in the development and commercialization of cannabinoid-based drugs, announced that it filed...
Jun 13, 2016The Israeli pharma company Therapix Biosciences, is joined by five internationally renowned experts, from Israel and the world, in the field of psychiatry and Tourette
Tel Aviv, Israel. Therapix Biosciences, (OTCQB: THXBY) (TASE: THXBY.TA) the pharma company specializing in the development and commercialization of cannabinoid-based drugs, announced that five...
Feb 17, 2016Therapix Biosciences completed successful studies in preclinical animal models towards a transition into clinical trialsThe Company successfully completed the preclinical episode of the “Joint-Pharma” program, which is aimed at the development of a product combining cannabinoid substances for treating neurological disorders, with an emphasis on Tourette’s syndrome under an orphan drug designation
Therapix Biosciences announces on February 17th, 2016 of successful results in preclinical studies it has conducted in order to confirm the “entourage effect”. The preclinical study examined...
Feb 16, 2016Therapix Biosciences signed a license agreement with Ramot for a novel technology for using ultra-low THC dosages for treating mild cognitive impairmentTherapix is using technology developed at the Faculty of Medicine of Tel Aviv University, in the context of the Company’s Brain-Bright Program
Therapix, a specialty pharma company engaged in the development of cannabinoid-based prescribed drugs, announced on February 15th, 2016 that it has entered into a definitive agreement with Ramot,...